How should penile arterial vascular health be assessed in a 46-year-old man with erectile dysfunction and low morning testosterone?

Assessment of Penile Arterial Vascular Health

Penile dynamic duplex ultrasonography (color Doppler ultrasound) after intracavernous injection of a vasoactive drug is the primary method to assess penile arterial vascular health, measuring peak systolic velocity (PSV) and end-diastolic velocity in the cavernosal arteries. 1

When to Perform Vascular Testing

Specialized vascular studies are not routine for every man with erectile dysfunction. They are indicated only in specific clinical scenarios: 1

• Young patients with a history of pelvic or perineal trauma who could benefit from potentially curative revascularization surgery or angioplasty 1
• Primary erectile dysfunction not caused by acquired organic disease or psychogenic disorder 1
• Patients with penile deformities requiring surgical correction (e.g., Peyronie's disease, congenital penile curvature) 1
• Complex endocrine or psychiatric disorders 1
• Medicolegal reasons (e.g., documentation of end-stage ED before penile prosthesis implantation) 1
• At the specific request of the patient or partner 1

For your 46-year-old patient with erectile dysfunction and low morning testosterone, vascular testing is not indicated unless he fails to respond to standard therapy (PDE5 inhibitors combined with testosterone replacement). 1, 2

The Standard Vascular Assessment Protocol

When vascular testing is indicated, the procedure follows this sequence: 1, 3

Step 1: Intracavernous Vasoactive Drug Injection

• An intracavernous injection of a vasoactive agent (typically alprostadil, papaverine, or a combination) is administered to induce maximal arterial dilation 1, 3
• This serves as the basic test and foundation for all subsequent vascular imaging 1, 3

Step 2: Penile Dynamic Duplex Ultrasonography (Color Doppler)

• Peak systolic velocity (PSV) is the most important parameter for arterial assessment: 3, 4, 5, 6
  • PSV < 25 cm/s indicates severe arterial insufficiency 5
  • PSV 25–29 cm/s indicates moderate arterial insufficiency 5
  • PSV 30–34 cm/s indicates mild arterial insufficiency 5
  • PSV ≥ 35 cm/s is generally considered normal 3
• End-diastolic velocity (EDV) and resistive index help assess venous occlusive dysfunction but are less reliable for arterial assessment 6
• Acceleration time of the cavernosal artery provides additional information about arterial stiffness and atherosclerotic disease 5

Step 3: Advanced Imaging (When Indicated)

If surgical revascularization is being considered, additional studies may include: 1, 3

• Selective internal pudendal arteriography to map arterial anatomy before revascularization surgery 1, 3
• Magnetic resonance imaging (MRI) or computed tomography (CT) angiography for detailed vascular mapping 3
• Dynamic infusion cavernosometry and cavernosography if venous leak is suspected 1, 3

Clinical Correlation: PSV and Cardiovascular Disease

Lower PSV values correlate strongly with systemic cardiovascular disease: 4, 6

• Men with PSV < 25 cm/s have significantly higher rates of ischemic heart disease 6
• A statistically significant association exists between decreasing PSV and higher grades of coronary artery disease 6
• PSV measurement can serve as a screening tool for underlying cardiovascular disease in men presenting with erectile dysfunction 6
• The difference between vascular age and chronological age (Δage) inversely correlates with PSV (β = -0.113, P < 0.0001), meaning worse arterial function predicts accelerated vascular aging 4

Biomarkers of Endothelial Dysfunction

Research has identified novel serum markers that correlate with penile arterial damage: 5

• Endothelial progenitor cells (EPCs) with immunophenotype CD45(−)/CD34(+)/CD144(+) 5
• Endothelial microparticles (EMPs) with immunophenotype CD45(−)/CD144(+)/annexin V(+) 5
• Men with arterial erectile dysfunction show significantly elevated EPC and EMP levels compared to men with psychogenic ED 5
• Among men with arterial ED, those with PSV < 25 cm/s have the highest EPC and EMP concentrations, confirming severe endothelial dysfunction 5

These biomarkers are currently research tools and not part of routine clinical practice. 5

Practical Algorithm for Your Patient

For a 46-year-old man with erectile dysfunction and low morning testosterone: 1, 2

Step 1: Confirm testosterone deficiency with a repeat morning total testosterone measurement 2

Step 2: Initiate testosterone replacement therapy, as this improves erectile function and enhances PDE5 inhibitor efficacy 1, 2, 7

Step 3: Start a PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) and titrate to maximum tolerated dose over at least 5–8 treatment attempts 1, 2

Step 4: Reassess after 3–6 months of combined therapy 2

Step 5: Only if treatment fails and the patient has no history of trauma or congenital abnormality, consider referral for penile duplex Doppler ultrasonography 1, 2

Critical Pitfalls to Avoid

• Do not order penile Doppler ultrasound as a first-line test—it is reserved for treatment failures or specific indications such as trauma or planned surgery 1, 2
• Do not interpret PSV in isolation—correlation with clinical response to intracavernous injection, patient age, cardiovascular risk factors, and testosterone status is essential 5, 6
• Do not overlook the cardiovascular implications—any man with documented arterial erectile dysfunction (PSV < 35 cm/s) should undergo comprehensive cardiovascular risk assessment, as erectile dysfunction predicts future cardiac events with a magnitude comparable to smoking 2, 4, 6
• Do not assume normal testosterone excludes vascular disease—arterial insufficiency and testosterone deficiency are independent contributors to erectile dysfunction 7, 5